Zacks: Analysts Anticipate AstraZeneca plc (NYSE:AZN) Will Post Earnings of $0.53 Per Share

Analysts expect AstraZeneca plc (NYSE:AZN) to report earnings of $0.53 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AstraZeneca’s earnings, with the lowest EPS estimate coming in at $0.50 and the highest estimate coming in at $0.56. AstraZeneca reported earnings per share of $0.50 in the same quarter last year, which would suggest a positive year over year growth rate of 6%. The company is scheduled to report its next quarterly earnings report on Thursday, October 22nd.

On average, analysts expect that AstraZeneca will report full-year earnings of $2.03 per share for the current fiscal year, with EPS estimates ranging from $1.94 to $2.05. For the next financial year, analysts forecast that the firm will post earnings of $2.56 per share, with EPS estimates ranging from $2.40 to $2.75. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AstraZeneca.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.04. The business had revenue of $6.28 billion during the quarter, compared to analysts’ expectations of $6.27 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 earnings per share.

AZN has been the subject of several recent analyst reports. Cowen upped their target price on AstraZeneca from $55.00 to $60.00 in a research note on Wednesday, June 10th. Berenberg Bank assumed coverage on AstraZeneca in a research note on Tuesday. They issued a “buy” rating on the stock. UBS Group reissued a “sell” rating on shares of AstraZeneca in a research note on Thursday, June 4th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, July 29th. Finally, Zacks Investment Research lowered shares of AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 price target on the stock. in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $61.00.

Shares of AZN stock traded up $0.37 during trading on Tuesday, hitting $55.12. The company had a trading volume of 293,536 shares, compared to its average volume of 5,242,847. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a market capitalization of $143.68 billion, a P/E ratio of 66.30, a price-to-earnings-growth ratio of 1.63 and a beta of 0.50. The stock’s 50-day moving average price is $55.32 and its 200 day moving average price is $52.26. AstraZeneca has a one year low of $36.15 and a one year high of $64.94.

The business also recently declared a semi-annual dividend, which was paid on Monday, September 14th. Investors of record on Friday, August 14th were issued a $0.45 dividend. The ex-dividend date of this dividend was Thursday, August 13th. This represents a dividend yield of 2.5%. AstraZeneca’s dividend payout ratio (DPR) is presently 50.29%.

Large investors have recently bought and sold shares of the business. Capital International Investors grew its stake in AstraZeneca by 23.4% in the 1st quarter. Capital International Investors now owns 28,325,620 shares of the company’s stock worth $1,265,021,000 after buying an additional 5,375,926 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of AstraZeneca by 3.3% during the 1st quarter. Wellington Management Group LLP now owns 67,358,391 shares of the company’s stock valued at $3,008,227,000 after buying an additional 2,163,500 shares in the last quarter. Invesco Ltd. grew its position in shares of AstraZeneca by 24.2% during the first quarter. Invesco Ltd. now owns 10,826,008 shares of the company’s stock worth $483,490,000 after purchasing an additional 2,106,066 shares in the last quarter. Capital World Investors boosted its stake in AstraZeneca by 39.2% during the first quarter. Capital World Investors now owns 5,483,236 shares of the company’s stock valued at $244,878,000 after buying an additional 1,543,667 shares during the last quarter. Finally, GQG Partners LLC grew its stake in shares of AstraZeneca by 15.7% in the 2nd quarter. GQG Partners LLC now owns 9,186,554 shares of the company’s stock worth $486,087,000 after buying an additional 1,249,163 shares in the last quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.